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Abstract
Background: N-of-1 trials are multiple cross-over trials done in individual participants, generating individual
treatment effect information. While reporting guidelines for the CONSORT Extension for N-of-1 trials (CENT) and the
Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) already exist, there is no standardized
recommendation for the reporting of N-of-1 trial protocols.
Objective: The objective of this study is to evaluate current literature on N-of-1 design and reporting to identify
key elements of rigorous N-of-1 protocol design.
Methods: We will conduct a systematic search for all N-of-1 trial guidelines and protocol-reporting guidelines
published in peer-reviewed literature. We will search Medline, Embase, PsycINFO, CINAHL, the Cochrane
Methodology Register, CENTRAL, and the NHS Economic Evaluation Database. Eligible articles will contain explicit
guidance on N-of-1 protocol construction or reporting. Two reviewers will independently screen all titles and
abstracts and then undertake full-text reviews of potential articles to determine eligibility. One reviewer will perform
data extraction of selected articles, checked by the second reviewer. Data analysis will ascertain common features
of N-of-1 trial protocols and compare them to the SPIRIT and CENT items.
Discussion: This systematic review assesses recommendations on the design and reporting of N-of-1 trial protocols.
These findings will inform an international Delphi development process for an N-of-1 trial protocol reporting
guideline. The development of this guideline is critical for improving the quality of N-of-1 protocols, leading to
improvements in the quality of published N-of-1 trial research.
Keywords: Systematic review, N-of-1 trials, Clinical protocols, Guidelines, Single case experimental designs
Background
N-of-1 trials are a multiple cross-over trial design within
a single participant, wherein a participant receives all
treatments an equal number of times with at least two
tests of each treatment (e.g., ABAB) [1–4]. They have
been recommended for personalizing treatment since
the late 1960s [5, 6]. Though useful for situations where
substantial heterogeneity of treatment effects may be an
issue, N-of-1 trials are especially important when large
parallel group randomized controlled trials (RCTs) are not
feasible and evidence is limited, such as for evaluation of
rare diseases, many pediatric conditions, and patients with
co-morbid conditions or multiple concurrent treatments.
When done in series, these trials can also facilitate the devel-
opment of rigorous evidence in those populations [7–11].
Due to the design’s multiple cross-overs within a single
participant, some aspects of an N-of-1 trial require par-
ticular consideration for feasibility, including: (i) the
types of conditions (e.g., best if chronic and stable; if
episodic, then frequently occurring) or treatments (e.g.,
reversible, preferably with quick onset and quick offset)
that may be evaluated through the N-of-1 design; (ii)
some design constituents (e.g., shorter treatment period
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lengths preferable, presence or absence of washout); and
(iii) opportunities for participant contribution during the
design process (e.g., treatment and outcome choice pref-
erences). Methods of analysis of a series of N-of-1 trials,
including meta-analysis of N-of-1 data, continue to be
refined, increasing their research value [12, 13].
Careful development of a clinical trial protocol is im-
portant for researchers, ethics review boards, funders,
and journals [14, 15]. Protocol reporting guidelines en-
sure that the specifics of the planned research trial are
reported in a transparent, accurate, standardized manner
[14, 16]. For reporting trial protocols, the Standard
Protocol Items: Recommendations for Interventional
Trials (SPIRIT) guideline [15] provides recommenda-
tions for essential elements to address in a clinical trial
protocol. A SPIRIT Extension for N-of-1 Trials (SPENT)
will help trialists report the important details unique to
this trial design. This synthesis of published guidelines
on N-of-1 trial protocol design will be the first step in
the development process of SPENT [16].
This systematic review will search for both N-of-1
protocol reporting guidelines as well as clinical trial de-
sign recommendations. A preliminary exploratory search
suggested no N-of-1 protocol reporting guidelines. A
number of articles detail methodological recommenda-
tions for N-of-1 trials [1, 17–23], including the Consoli-
dated Standards of Reporting Trials (CONSORT)
Extension for N-of-1 Trials (CENT) [8]. Furthermore,
this review includes psychological as well as medical lit-
erature databases to increase identification of relevant
N-of-1 design guidelines.
Objectives
The purpose of this review is to systematically identify
published guidelines and reporting guidelines relevant to
N-of-1 trial protocols. The main goal is to identify a list
of relevant N-of-1 trial protocol items that might be in-
cluded in an N-of-1 protocol reporting guideline, and
summarize similarities and gaps to items in the SPIRIT
and CENT reporting guidelines.
Methods and design
This systematic review will be done using recommen-
dations from Systematic Reviews by the Centre for
Reviews and Dissemination [24] and is based on the
SPIRIT and CENT systematic review protocols [8, 14].
It is being reported using the 2015 Preferred Report-
ing Items for Systematic Reviews and Meta-Analyses:
Protocols (PRISMA-P) statement items [25]. This
protocol is not registered with the International Pro-
spective Register of systematic reviews (PROSPERO)
because a review of protocol guidelines does not meet
the inclusion criteria [26].
Criteria for document inclusion
Types of documents
Published, peer-reviewed articles written in English will
be included if they describe a guideline for developing
and conducting an N-of-1 trial or for reporting an N-of-
1 trial protocol.
Eligibility criteria for guidelines of interest
Potential articles will be eligible for inclusion if they con-
tain an explicit, itemized guide detailing the content or
headings for designing or reporting a complete N-of-1
trial protocol [14] or aspects of a such a protocol. Due
to lack of specificity, articles that simply describe a gen-
eric ABAB trial design for the purpose of reviewing or
contrasting different trial designs, or that pertain to
other single subject research designs, will be excluded.
Information sources and their search strategies
Three strategies will be used for the search: (1) a system-
atic review of the literature; (2) searching references
cited in the N-of-1 articles found by the search strategy;
and (3) requests for guidelines specific to N-of-1 trials
will be sent to 31 large private and public research and
funding organizations in North America, Europe, and
Australia.
Systematic review of the literature The following data-
bases will be searched: Medline (Ovid interface, 1946 to
Feb 2015), Embase (Ovid interface, 1974 to Feb 2015),
PsycINFO (Ovid interface, 1806 to Feb 2015), CINAHL
(EBSCOHost interface, 1982 to present), Cochrane
Methodology register (Wiley interface, through to 2015),
CENTRAL (Wiley interface, through to 2015), and
the NHS Economic Evaluation Database (Wiley inter-
face, coverage dates unstated). The search strategy for
Medline can be found in Appendix 1. It will be modi-
fied as appropriate for the individual database search
parameters.
This search protocol was developed in collaboration
with a health research librarian, based on a previous N-
of-1 trial systematic review protocol (used for the CENT
guidelines [8]), the protocol used for the SPIRIT Guide-
lines [14], and a review of the keywords from several N-
of-1 guidance documents [1, 20, 27]. The search proto-
col was validated for effectiveness [28] using a small set
of well-established N-of-1 methodology documents [1,
18, 19, 22, 27, 29].
Data management
Screening All search result references will be directly
imported into DistillerSR®, an on-line program for
systematic review data management and analysis. For
Stage 1 screening, two reviewers (AP and SP) will
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independently scan titles and abstracts of all references
to identify potentially relevant articles according to the
inclusion/exclusion criteria. Articles meeting the inclu-
sion criteria, and those where there is any uncertainty,
will move to Stage 2 where full articles will be screened.
The reviewers developed the screening questions for
Stage 1 and 2 based on the inclusion/exclusion criteria,
and tested the forms, resolving any discrepancies. For
both stages, any differences of screening status between
the two reviewers will be discussed, and a third referee
(AO) will resolve remaining disagreements.
Data extraction All articles selected from Stage 2 will
be reviewed using a data extraction form to identify po-
tential standard recommended N-of-1 protocol items.
The form, reviewed by the team, includes all SPIRIT
guideline items, CENT guideline items that are not ad-
dressed by SPIRIT, and additional items from our refer-
ence articles [1, 18, 19, 22, 29] that address key N-of-1
trial design issues not otherwise addressed in SPIRIT
and CENT. Additionally, to learn more about the devel-
opment of the included guidelines, we have included
items from SPIRIT’s initial systematic review protocol
that are specific to the development process of the
guidelines. The screening form includes text boxes for
additional description for N-of-1-specific items and a
final open-ended text box for any additional notes on
topics of relevance not in the screening list. Piloting of
the data extraction form using the N-of-1 guidance doc-
uments will occur before undertaking the data extrac-
tion. The screening form is in Additional file 1; the key
identifying each item’s reporting guideline source is
available on request.
Because data extraction is focused on verifying if each
item is present in the article, one reviewer will extract
(AP), and a second (SP) will check a 15% sample from
each paper for extraction accuracy. Any differences of
data extraction between the two reviewers will be dis-
cussed, and a third referee (AO) will resolve remaining
disagreements; if greater than 20% disagreement, full re-
view will be considered.
Data analysis and synthesis
Extracted data will be used for descriptive statistical ana-
lysis (n, %, per item and per reporting topic headings in
the data extraction form), and the median number of
items per guideline. For items represented in at least
50% of the articles, frequencies of representation for
each item in the SPIRIT and CENT statement items will
be calculated to identify similarities, gaps, and topics not
identified in SPIRIT and CENT. To identify other issues
or items not addressed by the data extraction form, syn-
thesis of any notes or comments made in the screening
form will be assessed using basic qualitative descriptive
analysis, in which core topics or ideas are tabulated and
clustered, staying within the language and meaning of
the note text [30, 31]. This analysis process will be
directed by one reviewer (AP) and reviewed by a second.
All protocol-specific results and extracted qualitatively-
identified topics will form the starting list for the devel-
opment of SPENT. This list will be assessed and refined
using a sample of published and unpublished N-of-1
trial protocols, followed by an international Delphi
process.
Discussion
This systematic review will find and synthesize the rec-
ommendations on the development and publishing of
N-of-1 trial protocols. The results will be reported using
the Preferred Reporting Items for Systematic reviews
and Meta-Analyses (PRISMA) Statement [32].
Within single subject research, N-of-1 is one of many
different established trial designs. The associated termin-
ology regarding these designs is becoming standardized
[8, 23]. However, in older articles, “N-of-1” may have re-
ferred to any form of research in a single person. Con-
versely, an actual N-of-1 trial may not have used the
explicit N-of-1 designation. Therefore other older and
more generic terms are included in the search strategy.
The search strategies are not optimized to capture
non-English N-of-1 terminology. However, many jour-
nals indexed in PubMed provide English abstracts and
MeSH or key terms. A search for “n-of-1” and “n of 1”
in the non-English languages included in PubMed found
only eight articles, all N-of-1 trials, from 1989 to 2014.
Several of these non-English language articles only cited
English N-of-1 design articles referenced in this proto-
col; non-English language N-of-1 guidelines were not
identified. It is therefore assumed that excluding non-
English language articles will not likely exclude any key
relevant knowledge from this systematic review.
Some medical epistemologists argue that N-of-1 RCTs
offer the most rigorous form of evidence-based medicine
by combining individual patient values, randomization,
and clinician expertise into a single experiment or clin-
ical decision-making event [2, 3, 33]. They may be a use-
ful option for addressing the personalized care
recommendations of the US Patient-Centered Research
Institute (PCORI) and the Canadian Strategy for Patient-
Oriented Research (SPOR) [3]. Despite these advantages
and calls for the routine use of N-of-1 trials in clinical
practice and decision-making, N-of-1 trials remain an
underused method and strategy in research and practice.
The broad scope of this systematic review will help pro-
vide an appropriate basis for developing rigorous N-of-1
trial protocols, and an N-of-1 trial protocol reporting
guideline (SPENT). Specifically, the results will form the
basis for the Delphi process needed to assess and
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develop possible items in SPENT. In turn, these should
strongly support improvements in the implementation
of patient-centred research and the quality of published
N-of-1 trial research.
Appendix 1 – Electronic search strategies
[mp = title, abstract, original title, name of substance
word, subject heading word, keyword heading word,
protocol supplementary concept word, rare disease sup-
plementary concept word, unique identifier]
MEDLINE
Medline 10 Feb 2015 skj
1. n-of-1.mp.
2. n of 1.tw.
3. (individual$ adj3 trial$).mp.
4. (individual$ adj3 test$).tw.
5. ((single or individual) adj (subject or patient or case)
adj3 (trial$ or design)).tw.
6. individuali#ed medication effectiveness test$.tw.
7. patient$ as their own control$.tw.
8. abab.ti,ab.
9. or/1-8
10.Double-Blind Method/
11.Research Design/
12.Randomized Controlled Trials as Topic/
13.cross-over studies/
14.Placebos/
15.Guidelines as Topic/
16.bayes theorem/
17.frequentist.mp.
18.or/10-17
19.9 and 18
20.limit 19 to humans
21.limit 20 to English language
Additional file
Additional file 1: Level 3 Data Extraction Questions. (DOC 31 kb)
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